BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease.
Caryl E SortwellMallory L HackerDavid Luke FischerPeter E KonradThomas L DavisJoseph S NeimatLily WangYanna SongZach R MattinglyAllyson Cole-StraussJack W LiptonP David CharlesPublished in: Neuromodulation : journal of the International Neuromodulation Society (2021)
Genotyping for the rs6265 polymorphism may be useful for predicting long-term response to drug therapy and counseling Parkinson's disease patients regarding whether to consider earlier subthalamic nucleus deep brain stimulation. Validation in a larger cohort of early-stage Parkinson's disease subjects is warranted.
Keyphrases
- deep brain stimulation
- parkinson disease
- early stage
- obsessive compulsive disorder
- end stage renal disease
- ejection fraction
- newly diagnosed
- squamous cell carcinoma
- smoking cessation
- stem cells
- peritoneal dialysis
- genome wide
- type diabetes
- dna methylation
- bone marrow
- insulin resistance
- mesenchymal stem cells
- lymph node
- human immunodeficiency virus
- genetic diversity
- adverse drug
- hiv infected
- replacement therapy
- single cell